4322
/ 1
Min Read
The pharma company is expecting a funding of $100 million and fits in with Aurobindo’s strategic road map of upping its presence in Eastern Europe.
Aurobindo Pharma is eyeing US $1.7-billion privately held European Business in the form of a Canadian Drug Maker Apotex. Known for its high profile litigations in the US against MNC pharma players, Apotex has put on the block its European operations as part of a wider consolidation effort
According to the sources who spoke to the newsperson, the pharma company is expecting a funding of US $100 million and fits in with Aurobindo’s strategic road map of upping its presence in Eastern Europe through bolt-on acquisitions. No other information could be elicited from the I-bankers.
